Principal Investigator
Alvaro Alencar
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20221346
Clinical Trial Summary
A phase 1/2 study of Zanubrutinib and Tafasitamab in mantle cell lymphoma
Phase
Phase I/II
Funding Agency/Sponsor
Institutional
Disease
Lymphoma
Contact Information
Phone Number
305-243-2647